Azelastine Efficacy and Safety for Allergic Rhinitis

Efficacy for Runny Nose

Azelastine nasal spray is highly effective for treating runny nose (rhinorrhea) in allergic rhinitis, with rapid onset of action within 15 minutes and proven superiority over placebo in reducing nasal symptoms including rhinorrhea, as recommended by the American Academy of Allergy, Asthma, and Immunology 1

Combining azelastine with fluticasone propionate nasal spray provides greater symptom reduction than either agent alone, with 40% relative improvement over monotherapy, according to the American College of Allergy, Asthma, and Immunology 2
Combination therapy reduced Total Nasal Symptom Scores by 5.31-5.7 points compared to 3.25-4.54 for azelastine alone and 3.84-5.1 for fluticasone alone, as reported by the American Academy of Allergy, Asthma, and Immunology 2
This combination is particularly beneficial for patients who failed previous oral antihistamine therapy, as stated by the American College of Allergy, Asthma, and Immunology 1, 3

Azelastine offers a faster onset than oral antihistamines, working within 15 minutes vs hours for oral agents, as noted by the American Academy of Allergy, Asthma, and Immunology 1
Azelastine is effective for nasal congestion, relieving congestion in addition to runny nose, sneezing, and itching, according to the American College of Allergy, Asthma, and Immunology 1, 3

The American Academy of Otolaryngology-Head and Neck Surgery recommends azelastine nasal spray, with somnolence rates ranging from 0.9% to 11.5%, though more recent studies show rates of 0.4% to 3%, comparable to placebo 4, 5
Azelastine nasal spray acts within 15 minutes, providing rapid onset of action, and is recommended for patients with moderate to severe symptoms requiring treatment 6

The American Academy of Otolaryngology-Head and Neck Surgery recommends azelastine 0.1% (Astelin) 1-2 sprays per nostril twice daily for ages ≥6 years 4
The American Academy of Otolaryngology-Head and Neck Surgery also recommends azelastine 0.15% (Astepro) 1-2 sprays per nostril twice daily for ages ≥6 years 4

Patients should be counseled about potential somnolence, particularly when initiating therapy, though rates are generally low and comparable to placebo 4, 5
No specific contraindications are listed for azelastine formulations, but patients should be monitored for signs of somnolence at initiation, especially in patients operating machinery or driving 4, 5, 6, 7

Azelastine is a second‑generation H1‑receptor antagonist that lacks significant anticholinergic activity, so it does not raise intra‑ocular pressure in individuals with glaucoma. 8

The component that poses a risk for glaucoma in combination cold preparations is the decongestant pseudoephedrine; antihistamines such as azelastine do not share this risk. 8, 9
First‑generation antihistamines with anticholinergic properties can increase intra‑ocular pressure, whereas azelastine does not have this mechanism of action. 8, 9

Expert guidelines suggest using ipratropium bromide nasal spray as an alternative when first‑generation antihistamine/decongestant combinations are contraindicated in glaucoma patients; azelastine nasal spray is not listed as contraindicated. 8, 9

Oral or nasal decongestants (e.g., pseudoephedrine, oxymetazoline) should be avoided because they can elevate intra‑ocular pressure via sympathomimetic effects. 8, 9
First‑generation antihistamines with strong anticholinergic activity (e.g., diphenhydramine, brompheniramine) should be avoided as they may worsen glaucoma. 8, 9